Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Cetuximab for oropharyngeal cancer: latest data from De-ESCALaTE

Hisham Mehanna • 22 Oct 2018
ESMO 2018
Head and Neck Cancer Cetuximab Cisplatin
De-ESCALaTE

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, presents at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Mehanna highlights data from the De-ESCALaTE trial comparing cetuximab vs. cisplatin in patients with HPV-positive, low-risk oropharyngeal cancer who are receiving radical radiotherapy (ISRCTN33522080; NCT01874171).

More from Hisham Mehanna

2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna • 30 Sep 2019
2:31
Changes in the staging system for HPV+ cancer patients
Hisham Mehanna • 29 Nov 2018
2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna • 29 Nov 2018

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals